Morgan Stanley upgraded Kymera Therapeutics (KYMR) to Overweight from Equal Weight with a price target of $79, up from $49. The company reported Phase 1 data for STAT6 degraded KT-621 thtat the firm believes addressed key questions on safety and target knockdown, the analyst tells investors in a research note. The firm added that the data increases its confidence in KT-621’s ability to compete across large immunology and inflammation indications and in Kymera’s platform more broadly.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics price target raised to $60 from $52 at Citi
- Kymera Therapeutics upgraded to Buy at BofA after KT-621 data
- Kymera Therapeutics upgraded to Buy from Neutral at BofA
- Oppenheimer bullish on Nurix as Sanofi opt-in, competitor data derisk STAT6
- Kymera Therapeutics Discusses Phase 1 Study Results